Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Maternal Syphilis During Pregnancy - Baby Not Yet Delivered, Congenital Syphilis
Interventions: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 4
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 1 more

Conditions: RSV Infection
Interventions: EDP-938, Fluconazole; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions: Ixekizumab Prefilled Syringe; Drug
Lead sponsor: Massachusetts Eye Research and Surgery Institution; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Chronic Hepatitis B
Interventions: TDF, Peg-IFN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 17 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: NNRTI, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more

Conditions: HIV Infections
Interventions: Face-to-face training, Distance training, Popular Opinion Leader (POL); Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: X-Linked Lymphoproliferative Disease, Lymphoproliferative Disease, Genetic Diseases, X-Linked
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Injuries, Traumatic
Interventions: Standard care plus infrascans; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • Tucson, Arizona

Conditions: Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
Interventions: EPOCH-R, EPOCH-RR; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 22 more

Conditions: Uveitis
Interventions: Dose 2 gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 33
States / cities: Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: Infectious Disease, Neoplasms, Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89), Endocrine, Nutritional and Metabolic Diseases (E00-E89), Mental and Behavioural Disorders, Diseases of the Nervous System, Diseases of the Eye and Adnexa, Diseases of the Ear and Mastoid Process, Diseases of the Circulatory System, Diseases of the Respiratory System, Diseases of the Digestive System, Diseases of the Skin and Subcutaneous Tissue, Diseases of the Musculoskeletal System and Connective Tissue, Diseases of the Genitourinary System, Pregnancy, Childbirth and the Puerperium, Certain Conditions Originating in the Perinatal Period, Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99), Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified, Injury, Poisoning and Certain Other Consequences of External Causes, External Causes of Morbidity and Mortality, Factors Influencing Health Status and Contact With Health Services
Interventions: Not listed
Lead sponsor: Anova Enterprises, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: HIV Positive, Marijuana Smoking
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV (Human Immunodeficiency Virus), AIDS (Acquired Immunodeficiency Syndrome)
Interventions: VIP app without HIV-related symptom strategies., VIP app that delivers HIV-related symptom strategies.; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Diseases, Infectious
Interventions: Trimethoprim-sulfamethoxazole, Placebo group; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
Interventions: Vitamin E, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: HIV Infections
Interventions: raltegravir, Study NNRTI, Study PI; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: San Francisco, California

Conditions: SARS-CoV-2 Infection
Interventions: S-217622, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 2,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 53
States / cities: Guntersville, Alabama • Tempe, Arizona • Tucson, Arizona + 43 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, mRNA-1647; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Peoria, Illinois • Lenexa, Kansas • Lexington, Kentucky + 3 more

Conditions: Blastomycosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Conditions: Cryptococcosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Skin Disease, Bacterial, Abscess
Interventions: Trimethoprim-Sulfamethoxazole; Drug
Lead sponsor: Lucy Holmes, MD; Other
Eligibility: 3 Months to 17 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Inflammation, Pathologic Processes
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Point-Of-Care Testing for Congenital Syphilis in Mothers and Newborns

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations

Genetic Studies of X-linked Lymphoproliferative Disease

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

AnovaOS Network Powered Patient Registry

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

Vitamin E for NASH Treatment in HIV Infected Individuals

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults